Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. Small-cap stocks advanced once again in the first quarter of 2021. However, there was a rather considerable disparity among the two style indexes, as the Russell 2000® Growth Index (up 4.87%) significantly lagged its Russell 2000® Value Index counterpart (up 21.16%). You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

Carillon Eagle Small Cap Growth Fund, in their Q1 2021 investor letter, mentioned Amicus Therapeutics, Inc. (NASDAQ: FOLD), and shared their insights on the company. Amicus Therapeutics, Inc. is a Philadelphia, Pennsylvania-based biopharmaceutical company that currently has a $2.5 billion market capitalization. Since the beginning of the year, FOLD delivered a -57.97% return, while its 12-month gains are up by -18.17%. As of May 04, 2021, the stock closed at $9.70 per share.

Here is what Carillon Eagle Small Cap Growth Fund has to say about Amicus Therapeutics, Inc. in their Q1 2021 investor letter:

“Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. The firm’s shares slumped after it reported disappointing results in the phase three trial for its drug to be used in the treatment of late-onset Pompe disease (LOPD). Unfortunately, the trial data did not generate statistical significance in the primary endpoint.”


Our calculations show that Amicus Therapeutics, Inc. (NASDAQ: FOLD) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Amicus Therapeutics, Inc. was in 37 hedge fund portfolios, compared to 38 funds in the third quarter. FOLD delivered a -51.48% return in the past 3 months.

The top 10 stocks among hedge funds returned 231.2% between 2015 and 2020, and outperformed the S&P 500 Index ETFs by more than 126 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Here you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 15 best innovative stocks to buy to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.